ArticleStem cell reports2020
Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Article in Stem cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2025Pooled it
- Bioengineering trends in female reproduction: a systematic review.Human reproduction update · 2022Pooled it
- Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids.Cancer biology & therapy · 2026Article
- Protocol for generating and culturing high-grade serous ovarian carcinoma organoids from fresh or cryopreserved patient samples.STAR protocols · 2026Article
- An organoid-guided platform for ovarian cancer: enabling prediction of patients' chemotherapy response.Journal of ovarian research · 2026Article
- Patient-derived organoids in gynaecological cancers: emerging tools for therapy and disease modelling.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Decoding the association between platinum resistance and HPV status in cervical cancer using organoid models.BMC biology · 2026Article
- Organoid models: Regulations and prospects for the development of investigational new drugs.Chinese medical journal · 2026Review
- Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.Journal of advanced research · 2026Article
- Individual chemotherapy for patients colorectal cancer based on patient-derived tumor-like cell clusters.World journal of gastrointestinal surgery · 2026Article
- Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids.BMC medicine · 2026Article
- MRCKα represses GEF-H1 mediated RhoA activation to promote ovarian cancer spheroid growth and invasion.bioRxiv : the preprint server for biology · 2026Article
- Molecular subtype-specific breast cancer organoids: development of an FGF-free estradiol valerate culture system for precision drug screening.Cancer cell international · 2026Article
- Organoids and AI-integrated models in ovarian cancer research: the future of personalized therapy.Frontiers in oncology · 2026Review
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
- Inflammasomes meet organoids and artificial intelligence: unraveling the complexity of gynecological inflammation.Frontiers in immunology · 2026Review
- Engineering immune-competent niches: strategies, applications, and translational hurdles in ovarian cancer organoid models.Frontiers in immunology · 2026Review
- EPI-SauriCas9-based mouse ovarian cancer models recapitulating pten deletion in patients.Communications biology · 2025Article
- Review
- Patient-derived extracellular matrix from decellularized high-grade serous ovarian carcinoma tissues as a biocompatible support for organoid growth.Translational oncology · 2025Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) represents the most dismal gynecological cancer. Pathobiology is poorly understood, mainly due to lack of appropriate study models. Organoids, defined as self-developing three-dimensional in vitro reconstructions of tissues, provide powerful tools to model human diseases. Here, we established organoid cultures from patient-derived OC, in particular from the most prevalent high-grade serous OC (HGSOC). Testing multiple culture medium components identified neuregulin-1 (NRG1) as key factor in maximizing OC organoid development and growth, although overall derivation efficiency remained moderate (36% for HGSOC patients, 44% for all patients together). Established organoid lines showed patient tumor-dependent morphology and disease characteristics, and recapitulated the parent tumor's marker expression and mutational landscape. Moreover, the organoids displayed tumor-specific sensitivity to clinical HGSOC chemotherapeutic drugs. Patient-derived OC organoids provide powerful tools for the study of the cancer's pathobiology (such as importance of the NRG1/ERBB pathway) as well as advanced preclinical tools for (personalized) drug screening and discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.